Market Cap: $14.83B
NI
Neurocrine Biosciences, Inc.
NBIX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $14.83B
Neurocrine Biosciences (Ticker: NBIX) is making headlines with its groundbreaking findings from the CRENESSITY trial, presented at the ENDO 2026 conference. This trial marks a significant milestone, r…
Neurocrine Biosciences (Ticker: NBIX) is making headlines with the unveiling of new CRENESSITY data at the ENDO 2026 conference, which could have significant implications for the management of congeni…
Neurocrine Biosciences, Inc. (Ticker: NBIX) makes significant strides in treating congenital adrenal hyperplasia (CAH) with its investigational drug CRENESSITY (crinecerfont). Recent data from the Pha…
Neurocrine Biosciences (Ticker: NBIX) secures its role as a leading innovator in endocrinology with the recent unveiling of significant findings from its CAHtalyst® Adult study for the treatment of cl…
Neurocrine Biosciences (Ticker: NBIX) highlights crucial advancements in the treatment of tardive dyskinesia (TD) with the recent findings from its KINECT® 4 clinical trial. The study reveals that a r…
Neurocrine Biosciences (Ticker: NBIX) is set to showcase important long-term data on its treatment for congenital adrenal hyperplasia (CAH) at the upcoming ENDO 2026 conference. As the company prepare…
Neurocrine Biosciences has reached a definitive agreement to acquire Soleno Therapeutics for $53.00 per share, totaling an equity value of $2.9 billion. This strategic acquisition aims to enhance Neur…
New Guidelines Aim to Improve Management of Tardive Dyskinesia in Long-term Care Settings Neurocrine Biosciences, Inc. unveils a pivotal initiative at the PALTmed PALTC26 Annual Conference, offering a…
Neurocrine Biosciences Participates in Stifel 2026 Virtual CNS Forum to Highlight Commitment to Neurological Health Neurocrine Biosciences, Inc. engages in a forward-looking dialogue about advancement…
Neurocrine Biosciences: Leading Innovation in Neurological and Endocrine Therapeutics Neurocrine Biosciences, Inc., a key player in the biopharmaceutical landscape, is profoundly focused on addressing…
Neurocrine Biosciences Takes Center Stage at Stifel CNS Forum Neurocrine Biosciences, Inc., a leading biopharmaceutical company, announces its participation in the upcoming Stifel 2026 Virtual CNS For…
Neurocrine Biosciences Highlights Superior VMAT2 Target Engagement of INGREZZA® at Recent Conference Neurocrine Biosciences, Inc. presents compelling findings on its drug INGREZZA® (valbenazine) durin…
Neurocrine Biosciences Presents Groundbreaking VMAT2 Target Occupancy Findings Neurocrine Biosciences, Inc. unveils compelling data from a recent study at the American College of Neuropsychopharmacolo…
Neurocrine Biosciences: Pioneering Innovative Treatments for Complex Disorders Neurocrine Biosciences, Inc. stands out as a leading biopharmaceutical company focused on advancing treatments for neurol…
Neurocrine Biosciences: Pioneering Treatments for Neuroendocrine Disorders Neurocrine Biosciences, Inc. stands out in the biopharmaceutical landscape with its commitment to developing innovative treat…
Neurocrine Biosciences Accelerates Innovation in Neurology and Beyond Neurocrine Biosciences, Inc. is at the forefront of a transformative phase in its research and development strategy, as it aims to…
Neurocrine Biosciences Advances R&D Strategy with Focus on Neurological and Metabolic Disorders Neurocrine Biosciences, Inc. is embarking on an ambitious new phase in its research and development stra…
Neurocrine Biosciences Charts Ambitious R&D Pathway Neurocrine Biosciences, Inc. embarks on an ambitious new direction in its research and development strategy, underscoring its commitment to deliveri…
Neurocrine Biosciences Prepares for 2025 R&D Day to Showcase Neuroscience Advances Neurocrine Biosciences, Inc. is set to host its 2025 Research and Development Day on December 16, 2025, at 12:00 p.m.…
Neurocrine Biosciences Set to Showcase R&D Innovations at 2025 Event Neurocrine Biosciences, Inc. announces its 2025 Research and Development (R&D) Day, scheduled for December 16, 2025, at 12:00 p.m.…
Neurocrine Biosciences to Showcase R&D Advancements in Upcoming Event Neurocrine Biosciences, Inc. is gearing up for its 2025 Research and Development (R&D) Day, set to take place on December 16, 2025…
Neurocrine Biosciences Enhances Understanding of Tardive Dyskinesia Treatment with New Review Publication Neurocrine Biosciences, Inc. has made a significant contribution to the treatment landscape of…
Neurocrine Biosciences Advances Understanding of Tardive Dyskinesia Treatment with New Clinical Review Neurocrine Biosciences, Inc. recently publishes a peer-reviewed narrative review in CNS Spectrums…
Innovative Approaches in Drug Development: Roivant Sciences' Strategic Direction Roivant Sciences is making significant strides in the pharmaceutical industry through its innovative approach to drug d…
Innovative Drug Development: Roivant Sciences' Strategic Positioning in the Biopharmaceutical Landscape Roivant Sciences is at the forefront of transformative drug development, leveraging cutting-edge…